Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial
- PMID: 23485514
- DOI: 10.1179/1476830513Y.0000000060
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial
Abstract
Objectives: Multiple sclerosis is a neurodegenerative and demyelinating disease of central nervous system. High levels of oxidative stress are associated with inflammation and play an important role in pathogenesis of multiple sclerosis. This double-blind, randomized controlled clinical study was carried out to determine the effect of daily consumption of lipoic acid on oxidative stress among multiple sclerosis patients.
Methods: A total of 52 relapsing-remitting multiple sclerosis patients, aged 18-50 years with Expanded Disability Status Scale ≤5.5 were assigned to consume either lipoic acid (1200 mg/day) or placebo capsules for 12 weeks. Fasting blood samples were collected before the first dose taken and 12 hours after the last. Dietary intakes were obtained by using 3-day dietary records.
Results: Consumption of lipoic acid resulted in a significant improvement of total antioxidant capacity (TAC) in comparison to the placebo group (P = 0.004). Although a significant change of TAC (-1511 mmol/L, P = 0.001) was found within lipoic acid group, other markers of oxidative stress including superoxide dismutase activity, glutathione peroxidase activity, and malondialdehyde levels were not affected by lipoic acid consumption.
Discussion: These results suggest that 1200 mg of lipoic acid improves serum TAC among multiple sclerosis patients but does not affect other markers of oxidative stress.
Keywords: Glutathione peroxidase; Lipoic acid; Malondialdehyde; Multiple sclerosis; Oxidative stress; Reactive oxygen species; Superoxide dismutase; Total antioxidant capacity.
Similar articles
-
Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis.Int J Neurosci. 2013 Nov;123(11):776-82. doi: 10.3109/00207454.2013.801844. Epub 2013 Jun 17. Int J Neurosci. 2013. PMID: 23659338 Clinical Trial.
-
Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial.Neuroimmunomodulation. 2014;21(6):291-6. doi: 10.1159/000356145. Epub 2014 May 6. Neuroimmunomodulation. 2014. PMID: 24821457 Clinical Trial.
-
Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients.Clin Nutr. 2009 Apr;28(2):192-7. doi: 10.1016/j.clnu.2009.01.017. Epub 2009 Feb 20. Clin Nutr. 2009. PMID: 19231043 Clinical Trial.
-
[Antioxidant use as dietary therapy in patients with multiple sclerosis].Medwave. 2015 Jan 9;15(1):e6065. doi: 10.5867/medwave.2015.01.6065. Medwave. 2015. PMID: 25629306 Review. Spanish.
-
The Effects of Resveratrol on Oxidative Stress Markers: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Endocr Metab Immune Disord Drug Targets. 2020;20(5):718-727. doi: 10.2174/1871530319666191116112950. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31738139
Cited by
-
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.Drugs. 2018 Oct;78(15):1549-1566. doi: 10.1007/s40265-018-0984-5. Drugs. 2018. PMID: 30255442 Review.
-
Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review.Metab Brain Dis. 2019 Feb;34(1):39-52. doi: 10.1007/s11011-018-0344-x. Epub 2018 Nov 22. Metab Brain Dis. 2019. PMID: 30467770
-
Novel Drugs in a Pipeline for Progressive Multiple Sclerosis.J Clin Med. 2022 Jun 10;11(12):3342. doi: 10.3390/jcm11123342. J Clin Med. 2022. PMID: 35743410 Free PMC article. Review.
-
Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis.Curr Treat Options Neurol. 2019 May 6;21(6):26. doi: 10.1007/s11940-019-0566-1. Curr Treat Options Neurol. 2019. PMID: 31056714 Review.
-
Effects of Alpha Lipoic Acid Supplementation on Serum Levels of Oxidative Stress, Inflammatory Markers and Clinical Prognosis among Acute Ischemic Stroke Patients: A Randomized, Double Blind, TNS Trial.Adv Pharm Bull. 2020 Jun;10(2):284-289. doi: 10.34172/apb.2020.034. Epub 2020 Feb 18. Adv Pharm Bull. 2020. PMID: 32373498 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical